Amundi Asset Management US
PDLI

Amundi Asset Management US’s PDL BioPharma, Inc. PDLI Stock Holding History

Amundi Asset Management US’s Portfolio PDLI Stock Details PDLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-20,000
Closed -$53K – 1735
2018
Q3 		$53K Hold
20,000
– – ﹤0.01% 1561
2018
Q2 		$47K Hold
20,000
– – ﹤0.01% 1518
2018
Q1 		$59K Hold
20,000
– – ﹤0.01% 1476
2017
Q4 		$55K Buy
+20,000
New +$61.4K ﹤0.01% 1490

Other funds holding PDLI

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Kennedy Capital Management
Kennedy Capital Management St Louis, Missouri $5.65B AUM 61.31% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Connor, Clark & Lunn Investment Management (CC&L)
Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $52.8B AUM 58.98% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Brandes Investment Partners
Brandes Investment Partners La Jolla, California $14.3B AUM 23.11% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Amundi Asset Management US's PDLI Position: Q4 2018 in Review

Amundi Asset Management US sold out of PDL BioPharma, Inc. (PDLI) in Q4 2018, closing a stake of 20,000 shares — an estimated $53K sold.

Amundi Asset Management US first reported a position in PDLI in Q4 2017 and held it in 4 quarters. The position peaked at $59K in Q1 2018. 154 funds tracked by Wall St. Rank hold PDLI as of Q4 2018.

  • Amundi Asset Management US reported no remaining PDL BioPharma, Inc. position as of Q4 2018 after selling out during the quarter.
  • Amundi Asset Management US sold 20,000 PDL BioPharma, Inc. shares in Q4 2018, an estimated $53K.
  • Amundi Asset Management US first reported a position in PDL BioPharma, Inc. in Q4 2017 and held it in 4 quarters.
  • Amundi Asset Management US's PDL BioPharma, Inc. position peaked at $59K in Q1 2018.
  • 154 funds tracked by Wall St. Rank held PDL BioPharma, Inc. as of Q4 2018.

Based on Amundi Asset Management US's 13F filing for Q4 2018, filed 14 Feb 2019.